THE STUDY
First, this is a very small study and did not add any information of synuclein to the literature where much bigger study is out there (279 patients). Second, the authors do not specify the subtype of endometrial cancer knowing that synuclein is more expressed in type II carcinoma. Third, synuclein is known to have an impact on chemotherapy and we don't see it in this paper. So, it is very descriptive paper and of no real scientific value RESULTS & CONCLUSIONS The sutdy is very small and not dissected in a very good way b. Please clarify definition of "progression" for the biomarker. In Table 2 , there was no association with grade. For the stage, the dichotomized stage (I/II vs. III/IV) showed an association with the biomarker; however, to show "progression", appropriate analysis should be implemented from stage I to II, III, to IV.
REVIEWER
2. Pearson chi-square test and Fisher's exact test were both used to analyze the association of the binary γ-synuclein expression with clinicopathologic parameters. This raises a serious question when both tests showed different results (e.g., one test showed significant while the other was non-significant). Please clarify this issue. 3. In Table 1 and 2, some clinical variables were tested based on chi-square test (e.g., age and stage), while other clinical variables were tested based on Fisher test (e.g., Lymph node metastasis and normal vs. tumor). Please explain the rationale. 4. The Cox proportional hazard model was used for multivariate analysis to investigate if the biomarker is an independent prognostic factor. Since the Cox model is based on the proportional hazard assumption, prior to the analysis, the test for proportional hazard assumption is needed to ensure it does not violate the assumption. Please provide evidences to support the proportional hazard assumption. 5. It is strongly recommended that the survival plot includes the number of at risk for each group at each time interval.
VERSION 1 -AUTHOR RESPONSE
The histological subtype of all the tumor tissues was endometrioid adeno-carcinoma, so I changed the title of our study. The datas I got in my follow-up visit are authentic, since Guangxi is an impoverished province in China and The First Affiliated Hospital of Guangxi Medical University is the most advanced hospital in Guangxi province, and the people who come here are in the later period, normally patients of III/IV stages, therefore the mortality rate can be 26.7%,（in which 13.9%(5/36) was in stage I/II,45.8%(11/24) was in stage III/IV）Because of the inadequate fund, we only took 60 specimens of endometrioid endometrial cancer, who came to our hospital from 2004 to 2009. My research is to study the γ-synuclein expression and meaning in endometrioid endometrial cancer, based on the statistical theory, more specimens of the patients of III/IV stage is selected.
1. Article summary and Abstract: a. The authors claimed the biomarker has "predictive" value in endometrial carcinoma. However, all the results are related to prognosis. Please provide evidences to support the predictive value.
Answer: This is a retrospective study focus on the expression of γ-synuclein in endometrioid endometrial carcinoma, the predictive value is with respect to its prognostic value in endometrioid endometrial carcinoma. It may be a predictor of overall survival for endometrioid endometrial carcinoma.
b. Please clarify definition of "progression" for the biomarker. In Table 2 , there was no association with grade. For the stage, the dichotomized stage (I/II vs. III/IV) showed an association with the biomarker; however, to show "progression", appropriate analysis should be implemented from stage I to II, III, to IV. Answer: Firstly, the positive rate of γ-synuclein was uprised from grade 1 to grade 3 (from 40.9% to 58.3%), Although the significant correlation was not reached, there was a rising tendency from grade 1 to grade 3, maybe a large population of patients are needed for a signifiant conclusion. Secondly, Among 60 endometrial cancer patients, 26(43.3%) patients were in stage I, 10(16.7%) patients were in stage II, 23(38.3%) patients were in stage III，1(1.7%) was in stage IV. And the γ-synuclein expression in stage I, stage II, stage III, stage IV were 26.9%(7/26), 60.0%(6/10), 65.2%(15/23), 100.0% (1/1) respectively(p=0.018).The difference between stage I vs stage II, stage III vs stage IV were not signifcant,so we used the chi-square segmentation method and we found the that the difference of γ-synuclein between stage I/II vs. III/IV was significant(p=0.020). And the cancer in stage I/II is consider as "early stage"cancer; while the the cancer in stage III/IV is consider as "advanced stage"cancer. Thirdly, The study is focous on the role of the γ-synuclein expression in the aggressive progression of the endometrioid endometrial carcinoma, and we found that γ-synuclein is corrlated with the FIGO stage, the myometrial invasion and the lymph nodes metastasis.
